Prosecution Insights
Last updated: November 20, 2026
Application No. 18/275,287

CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE

Final Rejection §102
Filed
Aug 01, 2023
Priority
Feb 01, 2021 — provisional 63/144,358 +1 more
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Icahn School of Medicine At Mount Sinai
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1368 granted / 1633 resolved
+23.8% vs TC avg
Moderate +11% lift
Without
With
+11.2%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
52 currently pending
Career history
1672
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
12.1%
-27.9% vs TC avg
§102
26.6%
-13.4% vs TC avg
§112
34.2%
-5.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1633 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-4, 9-11, 15, 16, 18, 19, 21, 22, 32, 36, 43, 45, and 47 are pending in the instant application. Claims 2, 3, 22, 32, 36, 43, 45, and 47 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. Claims 1, 4 and 9 are rejected. Claims 10, 11, 15, 16, 18, 19, and 21 are objected. Drawings The drawings were received on September 14, 2026. These drawings are acceptable. The drawings are objected to because the font on some of the figures is difficult to read or is illegible. See Figures 3C-D, 8A-C, 9, 11A-B, 12B, 14A-B, 15A-C, 20A-C, and 21C. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Election/Restrictions It is noted that the search of the Markush-type claim has not been extended beyond the non-elected species wherein: R1 is PNG media_image1.png 66 90 media_image1.png Greyscale wherein R8 is PNG media_image2.png 68 94 media_image2.png Greyscale wherein n is 0; and the remaining variables are as defined. As prior art has been found which anticipates the above identified nonelected species, the Markush-type claims are rejected as follows and the subject matter of the claims drawn to nonelected species held withdrawn from consideration. Claims 1, 4, 9-11, 15, 16, 18, 19, and 21 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since art was found on the nonelected species, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. Response to Amendment and Arguments/Remarks The amendment and arguments/remarks filed on September 14, 2026 have been fully considered and entered into the application. With regards to the 35 U.S.C. 102(a)(1) rejections as being anticipated by Wang et al. and US 2007/0037752 A1, the grounds for rejection are moot in view of Applicant’s amendment and the rejections and claim objections have been withdrawn. However, this amendment has necessitated new grounds of rejection under 35 U.S.C. 102(a)(1), which are described below. New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 4 and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Khilya et al. (Khimiya Geterotsiklicheskikh Soedinenii (1985), (11), 1542-50). Khilya et al. discloses the compound PNG media_image3.png 174 296 media_image3.png Greyscale or PNG media_image4.png 106 142 media_image4.png Greyscale wherein R is CF3, Y is g, and R1=R2=H (see page 1273) which anticipates a compound of the claims wherein R1 is PNG media_image1.png 66 90 media_image1.png Greyscale wherein R8 is PNG media_image2.png 68 94 media_image2.png Greyscale wherein n is 0; R2 is CF3; R3, R4 and R6 are H; and R5 is alkoxy. Claim Objections Claims 10, 11, 15, 16, and 18 are objected to for depending on a previous rejected claim. However, even if the claims are amended to be in independent form, they would still not be in condition for allowance because they contain non-elected subject matter. In other words, the subject matter or species which are not embraced by the elected embodiment or the above identified nonelected species have been withdrawn from further consideration. Claims 19 and 21 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Aug 01, 2023
Application Filed
May 13, 2026
Non-Final Rejection mailed — §102
Sep 14, 2026
Response Filed
Nov 10, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799070
NANOMATERIALS COMPRISING ESTER-LINKED ACETALS
3y 5m to grant Granted Nov 17, 2026
Patent 12799120
SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES
3y 4m to grant Granted Nov 17, 2026
Patent 12799123
PYRAZOLOPYRIMIDINE ESTER COMPOUND
2y 8m to grant Granted Nov 17, 2026
Patent 12790341
sGC STIMULATORS
3y 0m to grant Granted Nov 10, 2026
Patent 12796312
ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE
3y 3m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+11.2%)
1y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1633 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month